Butanamide, N-hexyl-3-methyl

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: Butanamide, N-hexyl-3-methyl
• 英文别名: N-hexyl-3-methylbutanamide
• 化学式: C₁₁H₂₃NO
• mdl: MFCD01356840
• 分子量: 185.31
• InChiKey: PZJQRNSSYCNVMU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  13
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.91
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  正己胺 、 异戊酸酐 、 正丙胺 生成 Butanamide, N-hexyl-3-methyl
  参考文献：
  名称：

  HIRAKI, YUJI;TAI, AKIRA, CHEM. LETT., 1982, N 3, 341-344

  摘要：

  DOI：

文献信息

• METHODS AND COMPOUNDS FOR TARGETED AUTOPHAGY
  申请人：THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

  公开号：US20190290778A1

  公开（公告）日：2019-09-26

  Provided herein, inter alia, are methods and compounds for targeted autophagy.

  本文提供了针对靶向自噬的方法和化合物。
• COMPOUNDS AND METHODS FOR PURIFICATION OF SERINE PROTEASES
  申请人：Portola Pharmaceuticals, Inc.

  公开号：US20140186923A1

  公开（公告）日：2014-07-03

  Disclosed herein are compounds, compositions, methods and kits for purifying a serine protease and serine proteases purified with the compounds, compositions and methods.
• US9200268B2
  申请人：——

  公开号：US9200268B2

  公开（公告）日：2015-12-01
• US9644195B2
  申请人：——

  公开号：US9644195B2

  公开（公告）日：2017-05-09
• [EN] ANTI-GP73 ANTIBODIES AND IMMUNOCONJUGATES<br/>[FR] ANTICORPS ANTI-GP73 ET IMMUNOCONJUGUÉS
  申请人：CUREAB GMBH

  公开号：WO2018091724A1

  公开（公告）日：2018-05-24

  The present invention relates to antigen-binding molecules, preferably antibodies or antigen-binding fragments thereof, that specifically bind to a GP73, or to an antigenic portion thereof, wherein the antigen-binding molecule binds to an epitope within the extracellular part of GP73 that is internalized into a cell usually subsequent to proteolytic cleavage. The invention further relates to immunoconjugates comprising the antigen-binding molecules, in particular the anti-GP73 antibodies, or antigen-binding fragments thereof. The antigen- binding molecules and immunoconjugates of the invention may be administered alone, as a therapeutic conjugate or in combination with other naked antibodies, or with therapeutic agents, or with other immunoconjugates or as a diagnostic conjugate. The present invention also relates to nucleotide sequences encoding anti GP73 antibodies, and immunoconjugates, vectors and host cells containing the nucleotide sequences, and methods of making anti-GP73-antibodies. The antigen-binding molecules, antibodies and compositions of the invention are useful in diagnostic and therapeutic applications for diseases in which expression of GP73 is altered, in particular in which GP73 is overexpressed, such as cancer.